The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.
作者信息
Malvy Denis, Taburet Anne-Marie, de Lamballerie Xavier, Mentre France, Extramiana Fabrice
机构信息
Inserm 1219, University of Bordeaux, Bordeaux, France.
Department for Infectious and Tropical Diseases, University Hospital Center of Bordeaux, Bordeaux, France.
出版信息
PLoS Negl Trop Dis. 2020 Jun 25;14(6):e0008259. doi: 10.1371/journal.pntd.0008259. eCollection 2020 Jun.
Abstract
摘要
相似文献
1
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.法匹拉韦的安全性概况不应成为中止其在病毒性出血热中评估的首要理由。
PLoS Negl Trop Dis. 2020 Jun 25;14(6):e0008259. doi: 10.1371/journal.pntd.0008259. eCollection 2020 Jun.
2
Favipiravir: a new medication for the Ebola virus disease pandemic.法匹拉韦：一种应对埃博拉病毒病大流行的新药。
Disaster Med Public Health Prep. 2015 Feb;9(1):79-81. doi: 10.1017/dmp.2014.151. Epub 2014 Dec 29.
3
QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.埃博拉病毒感染患者接受法匹拉韦治疗期间的QTc间期延长
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. doi: 10.1371/journal.pntd.0006034. eCollection 2017 Dec.
4
Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.法匹拉韦在非人灵长类动物中的药代动力学及对出血热病毒未来疗效研究的启示
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01305-16. Print 2017 Jan.
5
Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.法匹拉韦治疗新冠门诊患者的疗效与安全性：一项随机对照试验的系统评价与荟萃分析
Am J Ther. 2024;31(3):e328-e331. doi: 10.1097/MJT.0000000000001649. Epub 2023 Aug 29.
6
A review on favipiravir: the properties, function, and usefulness to treat COVID-19.关于法匹拉韦的综述：性质、功能及在治疗 COVID-19 中的用途。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1029-1037. doi: 10.1080/14787210.2021.1866545. Epub 2020 Dec 29.
7
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.法匹拉韦（T-705）在病毒性出血热仓鼠模型中的药代动力学和生物分布变化
Antiviral Res. 2015 Sep;121:132-7. doi: 10.1016/j.antiviral.2015.07.003. Epub 2015 Jul 14.
8
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.新型核苷类似物治疗出血热病毒感染。
Chem Asian J. 2019 Nov 18;14(22):3962-3968. doi: 10.1002/asia.201900841. Epub 2019 Aug 7.
9
Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome.法维拉韦治疗发热伴血小板减少综合征患者的临床疗效及安全性评价。
EBioMedicine. 2021 Oct;72:103591. doi: 10.1016/j.ebiom.2021.103591. Epub 2021 Sep 23.
10
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.一项多中心非随机、非对照、单臂临床试验，评估使用法匹拉韦治疗伴有发热伴血小板减少综合征的患者的疗效和安全性。
PLoS Negl Trop Dis. 2021 Feb 22;15(2):e0009103. doi: 10.1371/journal.pntd.0009103. eCollection 2021 Feb.
引用本文的文献
1
Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.关于新冠病毒治疗、心血管结局及对新冠长期症状影响的全球视角：最新综述
J Community Hosp Intern Med Perspect. 2024 Mar 4;14(2):58-66. doi: 10.55729/2000-9666.1308. eCollection 2024.
2
Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials.法匹拉韦治疗新型冠状病毒肺炎患者的疗效与安全性：一项随机对照试验的Meta分析
Cureus. 2023 Jan 12;15(1):e33676. doi: 10.7759/cureus.33676. eCollection 2023 Jan.
3
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19.几种治疗新型冠状病毒肺炎的药物疗效综述
Life (Basel). 2022 Nov 1;12(11):1758. doi: 10.3390/life12111758.
4
High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea.几内亚两名埃博拉病毒病男性幸存者精液中携带埃博拉病毒，接受高剂量法匹拉韦治疗。
IDCases. 2022 Jan 21;27:e01412. doi: 10.1016/j.idcr.2022.e01412. eCollection 2022.
5
Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy.SARS-CoV-2 与心肌细胞的相互作用：心脏损伤和药物治疗潜在分子机制的研究进展。
Biomed Pharmacother. 2022 Feb;146:112518. doi: 10.1016/j.biopha.2021.112518. Epub 2021 Dec 9.
6
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.法维拉韦治疗 COVID-19 的疗效和安全性：临床试验的系统评价和荟萃分析。
Sci Rep. 2021 May 26;11(1):11022. doi: 10.1038/s41598-021-90551-6.
7
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.法匹拉韦在新型冠状病毒肺炎中的应用：对世界卫生组织数据库中报告的疑似药物不良事件的分析
Infect Drug Resist. 2020 Dec 14;13:4427-4438. doi: 10.2147/IDR.S287934. eCollection 2020.
8
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.一项关于使用法匹拉韦联合吸入用干扰素β-1b 治疗中重度 COVID-19 肺炎住院患者的随机对照开放标签试验。
Int J Infect Dis. 2021 Jan;102:538-543. doi: 10.1016/j.ijid.2020.11.008. Epub 2020 Nov 9.
本文引用的文献
1
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
2
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study.实验室发现、同情使用法匹拉韦和 2015 年几内亚埃博拉病毒病患者的结局：一项回顾性观察研究。
J Infect Dis. 2019 Jun 19;220(2):195-202. doi: 10.1093/infdis/jiz078.
3
QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.埃博拉病毒感染患者接受法匹拉韦治疗期间的QTc间期延长
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. doi: 10.1371/journal.pntd.0006034. eCollection 2017 Dec.
4
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.JIKI试验中埃博拉感染患者的法匹拉韦药代动力学显示浓度低于目标值。
PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.
5
Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.结合数据挖掘与实验室实验以发现导致QT间期延长的药物相互作用
J Am Coll Cardiol. 2016 Oct 18;68(16):1756-1764. doi: 10.1016/j.jacc.2016.07.761.
6
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.ZMapp治疗埃博拉病毒感染的随机对照试验。
N Engl J Med. 2016 Oct 13;375(15):1448-1456. doi: 10.1056/NEJMoa1604330.
7
Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days.几内亚埃博拉病毒病的卷土重来与一名精液中病毒持续存在超过500天的幸存者有关。
Clin Infect Dis. 2016 Nov 15;63(10):1353-1356. doi: 10.1093/cid/ciw601. Epub 2016 Sep 1.
8
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.法匹拉韦治疗埃博拉病毒病的实验性治疗（JIKI试验）：在几内亚进行的一项历史对照单臂概念验证试验。
PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar.
9
Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults.新型抗病毒药物法匹拉韦对健康日本成年人QT间期无影响。
Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. doi: 10.5414/CP202388.
10
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.抗疟药物甲氟喹与人心脏钾通道KvLQT1/minK和HERG的相互作用。
J Pharmacol Exp Ther. 2001 Oct;299(1):290-6.
Zotero 插件